Radiotherapy combined with temozolomide treatment for glioblastoma multiforme:a meta-analysis
Xiao-hu WANG,Li-yun GUO,Bin MA,Ke-hu YANG,Qiu-ning ZHANG,Nong CAO,Xiu-peng YE
DOI: https://doi.org/10.3781/j.issn.1000-7431.2010.12.013
2010-01-01
Tumor
Abstract:Objective: To assess the effectiveness and safety of radiotherapy combined with TMZ (temozolomide) for newly diagnosed GBM (glioblastoma multiform) compared with single radiotherapy. Methods: Computer retrieved was conducted to search for relevant RCTs (randomized controlled trails) in Cochrane Library (Issue 4, 2009), PubMed (Jan 1966-Dec 2009), EMBASE (Jan 1974-Dec 2009), Chinese Biomedical Literature Database (CBM, Jan 1978-Dec 2009), Chinese Scientific Journals Full Text Database (CSJD, Jan 1989-Dec 2009), China Journal Full Text Database (CJFD, Jan 1994-Dec 2009) and Wanfang Database (Jan 1997-Dec 2009). Two researchers assessed the quality of included trials and extracted data independently. The quality of included studies was critically evaluated and the data were analyzed by using the Cochrane Collaboration' s RevMan 5.0 software. Results: A total of five RCTs including 896 patients were involved in this meta-analysis. The results showed that radiotherapy combined with TMZ in newly diagnosed cases can raise the 18-month OS (overall survival) [RR (risk ratio) =2.46, 95% CI (confidence internal) : 1.11-5.46] and 24-month OS(AR = 2.88, 95% CI: 1.95-4.25)compared with radiotherapy alone, and improve the 6-month FFS (progression-free survival) (RR = 1.48, 95% CI: 1.22-1.78), 12-month PFS (RR =3.07, 95% CI: 2.17-4.34), 18-month PFS (RR =4.71, 95% CI: 2.51-8.84) and 24-month PFS (RR =7.47, 95% CI: 2.67-20.94), as well as improve 6-month TTP (time to progression) (RR = 1.51,95% CI: 1.07-2.13) and 12-month TTP (RR = 3.91, 95% CI: 1.59-9.61). There were no differences of incidences of grade 3-4 leukopenia (RR = 4.31, 95% CI: 0.77-24.31), grade 3-4 thrombocytopenia (RR = 4.03, 95% CI: 0.70-23.34) and grade 4 neutropenia (RR = 2.79, 95% CI: 0.12-67.10) between radiotherapy plus TMZ arm and radiotherapy alone arm. Conclusion: Radiotherapy combined with TMZ can raise the OS at 18 and 24 months, increase the PFS at 6, 12, 18 and 24 months, and improve TTP at 6 and 12 months. Treatment of radiotherapy combined with TMZ is more appropriate and effective than radiotherapy alone for newly diagnosed GBM after operation.